International Journal on Magnetic Particle Imaging IJMPI
Vol. 8 No. 1 Suppl 1 (2022): Int J Mag Part Imag
https://doi.org/10.18416/IJMPI.2022.2203071

Proceedings Articles

An iron-oxide nanoparticle with therapeutic capability in Magnetic Fluid Hyperthermia and diagnostic capability in MRI and MPI

Main Article Content

Federica Vurro (University of Verona), Marco Gerosa (University of Verona), Alice Busato (University of Verona), Matilde Muccilli (University of Verona), Emil Milan (University of Verona), Jeff Gaudet (Magnetic Insight), James Mansfield (Magnetic Insight), Patrick Goodwill (Magnetic Insight), Enrico Forlin (M.B.N. Nanomaterialia S.p.A), Filippo Gherlinzoni (Foundation for Nanotheranostics Research in Cancer Therapy, RNC), Gianni Morana (Foundation for Nanotheranostics Research in Cancer Therapy, RNC), Michele Gottardi (Foundation for Nanotheranostics Research in Cancer Therapy, RNC), Paolo Matteazzi (M.B.N. Nanomaterialia S.p.A), Max Wintermark (Department of Radiology, Stanford University Hospital), Adolfo Speghini (University of Verona), Pasquina Marzola (University of Verona)

Copyright (c) 2022 Federica Vurro, Marco Gerosa, Alice Busato, Matilde Muccilli, Emil Milan, Jeff Gaudet, James Mansfield, Patrick Goodwill, Enrico Forlin, Filippo Gherlinzoni, Gianni Morana, Michele Gottardi, Paolo Matteazzi, Max Wintermark, Adolfo Speghini, Pasquina Marzola

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

M55 belongs to a class of innovative nanomaterials, constituted by doped ferrite, with potential application in tumor therapy, as agents for Magnetic Fluid Hyperthermia (MFH), and in diagnosis, as contrast agents for MRI and MPI. Interestingly, such nanomaterials are characterized by a self-limiting temperature that can be modulated by adjusting the composition of the nanomaterial itself. M55 was coated with a double shell of citrate and glucose. We demonstrated that it has good capability as contrast agent for MRI and MPI. Moreover we tested its biocompatibility in a triple negative human breast cancer line and its efficacy as MFH agent in the same cell line. Despite relatively low SAR values in water solution, this agents was highly efficient in decreasing cell viability after two MFH treatments. Finally, we demonstrated that it can be useful to label cells for cell tracking in MPI. Although preliminary, these results are encouraging and push toward in vivo tests of such material. 

Article Details

References

[1] Gerosa M, Grande MD, Busato A, Vurro F, Cisterna B, Forlin E, Gherlinzoni F, Morana G, Gottardi M, Matteazzi P, Speghini A, Marzola P. Nanoparticles exhibiting self-regulating temperature as innovative agents for Magnetic Fluid Hyperthermia. Nanotheranostics, 5, 333, 2021.

[2] Matteazzi P, Gherlinzoni F, Gottardi M. Method for the production of sub-micrometric particles and their theranostic use in oncology with specific apparatus. European Patent EP 2961429B1 Pr. 28.02.2014.

[3] Chandrasekharan P, Tay ZW, Hensley D, Zhou XY, Fung BK, Colson C, Lu Y, Fellows BD, Huynh Q, Saayujya C, Yu E, Orendorff R, Zheng B, Goodwill P, Rinaldi C, Conolly S. Using magnetic particle imaging systems to localize and guide magnetic hyperthermia treatment: tracers, hardware, and future medical applications. Theranostics, 10, 2965, 2020.

[4] Lu Y, Rivera-Rodriguez A, Tay ZW, Hensley D, Fung KLB, Colson C, Saayujya C, Huynh Q, Kabuli L, Fellows B, Chandrasekharan P, Rinaldi C, Conolly S. Combining magnetic particle imaging and magnetic fluid hyperthermia for localized and image-guided treatment. Int J Hyperthermia,37, 14, 2020.

[5] Huang J, Chan PS, Lok V, Chen X, Ding H, Jin Y, Yuan J, Lao XQ, Zheng ZJ, Wong MC. Global incidence and mortality of breast cancer: a trend analysis. Aging (Albany NY),13,5748, 2021.

Most read articles by the same author(s)